Achieve Life Sciences (ACHV) Convertible Debt (2021 - 2026)

Achieve Life Sciences has disclosed Convertible Debt across 6 years of filings, most recently posting $9.3 million for Q1 2026.

• Quarterly Convertible Debt rose 7.68% year-over-year to $9.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.3 million (up 7.68% YoY) and the FY2025 annual result came in at $11.2 million, up 13.7% from the prior year.
• Convertible Debt declined to $9.3 million in Q1 2026, from $11.2 million in the prior quarter.
• Over five years, Convertible Debt peaked at $16.2 million in Q3 2023 and troughed at $8.7 million in Q1 2025.
• A 5-year average of $11.8 million and a median of $9.8 million in 2024 frame the typical range for Convertible Debt.
• Annual changes were most pronounced in 2024 — Convertible Debt tumbled 44.03% — and 2025, when it gained 13.7%.
• Tracing ACHV's Convertible Debt over 5 years: stood at $15.8 million in 2022, then grew by 2.74% to $16.2 million in 2023, then slumped by 39.26% to $9.8 million in 2024, then rose by 13.7% to $11.2 million in 2025, then declined by 16.66% to $9.3 million in 2026.
• Business Quant data shows ACHV's Convertible Debt at $9.3 million in Q1 2026, $11.2 million in Q4 2025, and $8.7 million in Q3 2025.